Artal Group’s Allogene Therapeutics ALLO Stock Holding History

Artal Group’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-100,000	Closed	-$2.73M	–	98
2019 Q3	$2.73M	Sell	100,000 -100,000	-50%	-$2.85M	0.11%	91
2019 Q2	$5.37M	Sell	200,000 -200,000	-50%	-$5.57M	0.22%	77
2019 Q1	$11.6M	Hold	400,000	–	–	0.47%	44
2018 Q4	$10.8M	Buy	+400,000	New	+$10.6M	0.4%	41

Other funds holding ALLO

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ROTUOC

Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return

Artal Group's ALLO Position: Q4 2019 in Review

Artal Group sold out of Allogene Therapeutics (ALLO) in Q4 2019, closing a stake of 100,000 shares — an estimated $2.73M sold.

Artal Group first reported a position in ALLO in Q4 2018 and held it in 4 quarters. The position peaked at $11.6M in Q1 2019. 116 funds tracked by Wall St. Rank hold ALLO as of Q4 2019.

Artal Group reported no remaining Allogene Therapeutics position as of Q4 2019 after selling out during the quarter.
Artal Group sold 100,000 Allogene Therapeutics shares in Q4 2019, an estimated $2.73M.
Artal Group first reported a position in Allogene Therapeutics in Q4 2018 and held it in 4 quarters.
Artal Group's Allogene Therapeutics position peaked at $11.6M in Q1 2019.
116 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2019.

Based on Artal Group's 13F filing for Q4 2019, filed 13 Feb 2020.